Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 26, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - March 26, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/26/17 - Two-thirds of Americans see docs who got paid by drug companies: Drexel University study
By a News Reporter-Staff News Editor at VerticalNews Health A majority of patients in the United States visited a doctor who received payments from drug companies, but most have no clue about it, according to a new Drexel University study. About 65 percent of those surveyed as a part of the study by Genevieve Pham-Kanter, PhD, an assistant profes
3/25/17 - Incysus Announces Preclinical Data Presentations of T Cell Immunotherapy Programs at Upcoming Medical Conferences [Sport360]
European Society for Blood and Marrow Transplantation 2017- Marseille, FranceMarch 27, 2017, 9:00- 9:10am Oral Session 3: Novel drugs and immunotherapies Title: Drug Resistant Lymphocyte Immunotherapy: Dose and Schedule OptimizationPresenter: Lawrence Lamb. American Association for Cancer Research 2017- Washington DC, USAApril 3, 2017, 8:00- 12:00p
3/25/17 - Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin
Attorney Advertising. On March 17, 2017, the nationally recognized class-action law firm of Keller Rohrback L.L.P. filed suit against the nation s three largest pharmacy benefit managers, Express Scripts, OptumRx, and CVS Caremark, and the three major insulin manufacturers, Sanofi-Aventis, Novo Nordisk, and Eli Lilly, who produce the well-known
3/25/17 - Neurens Phase 2 trial of trofinetide demonstrates significant clinical benefit in pediatric Rett syndrome [Sport360]
-Neuren Pharmaceuticals has reported top-line results for its Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15. Neuren now intends to discuss with the US Food and Drug Administration plans for a pivotal trial commencing in 2018 using the Rett Syndrome Behaviour Questionnaire as a primary efficacy measure, supported by the Clinical Gl
3/25/17 - Newron Presents Encouraging Detailed Results of Its Phase IIa Study with Evenamide in Patients with Schizophrenia
MILAN& MORRISTOWN, N.J. Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, today presented detailed results of a Phase IIa study with its unique sodium channel blocker, Evenamide, in patients with schizophrenia. The results w
3/25/17 - Paratek Pharmaceuticals Opens New Office in King of Prussia [Sport360]
-Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today opened its expanded office in King of Prussia, Pennsylvania. Our expanded home in King of Prussia provides our growing team with the physical space and resources to fuel our...
3/25/17 - Profound Medical Corp. Announces Management Change [Sport360]
-Profound Medical Corp. an emerging medical device company focused on prostate care, today announced that Steven Plymale has resigned his position as the Companys President and Chief Operating Officer to pursue other opportunities. The Company is also sponsoring a multicenter, prospective FDA- registered clinical trial, TACT, which is designed to f
3/25/17 - R.I. delegation, governor react to GOP health-care bill outcome [The Providence Journal, R.I.]
March 25 Here are reactions from members of the Rhode Island congressional delegation and Gov. Perhaps in the future, President Trump and the Republicans will listen to the American people who want us to focus on affordable health care for all Americans, lower prescription drug prices, and tax cuts for the middle-class, not the wealthiest. "
3/25/17 - Some win and some lose with 'Obamacare' still around
The old and the poor made out great when House Republicans failed Friday to dismantle Barack Obama's Affordable Care Act. The measure would have repealed major parts of Obama's health law, capping future funding for Medicaid and cutting tax increases for high-income families, health insurance companies and drugmakers. That's the tally according
3/25/17 - Study Findings from Bangor University Provide New Insights into Finance (Profitability and Market Value of Orphan Drug Companies: A Retrospective,...
By a News Reporter-Staff News Editor at Investment Weekly News Researchers detail new data in Finance. The news correspondents obtained a quote from the research from Bangor University, "Cases were defined as holders of orphan drug market authorisation in Europe or the USA between 2000-12. Control companies were selected based on their propensity
3/24/17 - "Fast Acting Orally Disintegrating Film" in Patent Application Approval Process (USPTO 20170056374)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Lee, Catherine; Wang, Chien-Chiao, filed on November 14, 2016, was made available online on March 9, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to TAHO Pharmaceuticals Ltd.
3/24/17 - 'Spider-Man' Glenn King Hopes His Potential Stroke-Saving Arachnid Molecule Makes It To Market
Media coverage has been huge in Britain and King's homeland, Australia, while U.S. attention has been scant. The years-long route from lab rats to FDA drug approval will be painstaking, exacting, and not necessarily successful. Larry Goldstein, professor and chairman of the Department of Neurology at the University of Kentucky and past chair of The
3/24/17 - AARP: Repealing Obamacare would hurt Hawaii's seniors
AARP, a nonprofit, nonpartisan, social welfare organization, released a scathing assessment of the Republican-proposed health care bill that's facing opposition from not only Democrats but a segment of the GOP in the U.S. House of Representatives. AARP is strongly against the age tax and other aspects of the bill that will give tax breaks to drug c
3/24/17 - Amring Pharmaceuticals Acquired Six ANDAs
By a News Reporter-Staff News Editor at Drug Week Amring Pharmaceuticals Inc., a generic pharmaceutical company, announced that it acquired six ANDAs from Luitpold Pharmaceuticals, Inc. and AlphaForce, L.L.P., a joint venture between Luitpold Pharmaceuticals, Inc. and Alphagen Laboratories Inc. Acquired ANDAs include niche otic and ophthalmic...
3/24/17 - Analyst Activity Wedbush Raises Its Price Target On Ascendis Pharma A/S (NASDAQ:ASND) to
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, a [?] The pos
3/24/17 - Analyst Activity Wedbush Raises Its Price Target On Ascendis Pharma A/S (NASDAQ:ASND) to $34.00
Analyst Ratings For Ascendis Pharma A/S (NASDAQ:ASND) Today, Wedbush raised its price target on Ascendis Pharma A/S (NASDAQ:ASND) to $34.00 per share. There are 1 hold rating, 2 buy ratings on the stock. The current consensus rating on Ascendis Pharma A/S (NASDAQ:ASND) is Buy (Score: 2.67) with a consensus target price of $30.67 per share, [?] Th
3/24/17 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Mar. 6, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on March 6, 2017. The SEC file number is 0001171843-17-001299.. A U.S. Securities and Exchange Commission filing is a formal
3/24/17 - AveXis Reports Topline Results from Phase 1 Trial of SMA Type 1 Gene Therapy [Syrian Arab News Agency]
AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy Type 1. The completion of our Phase 1 clinical study of AVXS-101, the first ever gene therapy studied for the.
3/24/17 - Avita Medical to Present at Needham Healthcare Conference
VALENCIA, Calif.& PERTH, Australia& LONDON Avita Medical Limited, a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017. The presentation will take place at 9:20am ET
3/24/17 - Beat market volatility with these stock option trade ideas for Citigroup, Exelixis, Gilead Sciences, Tesla Motors, and US Oil Fund!
By a News Reporter-Staff News Editor at Drug Week- InvestorsObserver issues critical PriceWatch Alerts for C, EXEL, GILD, TSLA, and USO. Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. Tesla Inc, formerly Tesla Motors Inc designs, develops,.
3/24/17 - Bharat Book Bureau: Global Transdermal Patch Market
"Global Transdermal Patch Market& Clinical Pipeline Outlook 2022" report discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market. Report highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
3/24/17 - Bharat Book Bureau: Infectious Disease Drugs: The Chinese Market
The Chinese infectious disease drug market is big, fast-growing and dominated by brands from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions that look for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehe
3/24/17 - Bioinformatics Market Is Expected To Growing At An Estimated CAGR of 21.2% From 2014 To 2020: Grand View Research, Inc.
According to new report by Grand View Research, The Global bioinformatics market size was valued at USD 3.51 billion in 2013. Growing clinical development of biopharmaceutical and increasing need for three dimensional drug designing technology are expected to drive the market. The global bioinformatics market is expected to reach USD 13.47 billion
3/24/17 - Biosimilar of costly inflammatory bowel disease therapy found safe and effective
By a News Reporter-Staff News Editor at Drug Week Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab, but at considerable cost. CT-P13 has been recently approved in the United States, the European Union, Australia, Canada, Japan, and many other countries.
3/24/17 - Biotech Stocks Under Scanner BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
This Friday, has initiated reports coverage on the following Biotechnology equities: BioDelivery Sciences International Inc., Sage Therapeutics Inc., Benitec Biopharma Ltd, and OncoGenex Pharmaceuticals Inc.. On Thursday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. ended the session...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement